Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers

Diabetic Foot Ulcer Clinical Trial

Official title:

A Prospective, Multi-center Observational Study to Investigate the Safety and Effectiveness of Sterilized, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05687656
• Other study ID #: TLS-IM-001
• Status: Completed
• Phase: N/A
• Start date: October 6, 2022
• Est. completion date: January 31, 2024

Study information

• Verified date: April 2024
• Source: ConvaTec Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Prospective, Non-Randomized, Multi-Center Observational Study

To determine the safety and effectiveness of InnovaMatrix AC porcine placental ECM therapy for the treatment of chronic, non-healing diabetic foot ulcers (DFUs)

Eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care wound therapy and offloading

Description:

This is a prospective, multi-center observational study . The trial will include 30 completed subjects at three (3) experienced clinical centers in the United States. The estimated enrollment period is 13 weeks. After completing a screening , the subjects will be enrolled and receive treatment followed for at least 12 weeks.

It is expected that the majority of the subjects will be recruited from patients being seen in the Investigators' practices. No minors will be included in the study and it is anticipated that there will be a roughly equal representation of male and female subjects. Further, no subjects will be excluded because of race or ethnicity and all efforts will be made to adequately represent the study population in the area in which they are chosen.

All subjects will be used for the analysis of efficacy and safety data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Male or female patients over 18 years of age who have given written informed consent in accordance with the ICH Good Clinical Practice (GCP) guideline. Female subjects must be either of non-childbearing potential or if of child bearing potential must satisfy the defined contraceptive criteria Exclusion criteria h.

2. Patients who are willing and able to attend all follow up visits

3. Subject has a known history of Type 1 or Type 2 diabetes with a HbA1c =12% . Has a diabetic foot ulcer classified by the Wagner classification 1 or 2 and at least 0.75cm2 and less than 5.0 cm2 in surface area as determined by photographic planimetry at the time of enrollment.

4. Index ulcer characteristics:

1. Ulcer present for = 30 days prior to (Day 0)

2. Index ulcer is located below the ankle: at least 50% of the ulcer surface area is below the malleolus.

5. Subject has Body Mass Index (BMI) = 45 at enrollment.

6. Subject has adequate circulation to the affected extremity, as demonstrated by at least one of the following within the past 30 days:

• Dorsum transcutaneous oxygen test (TcPO2) with results = 30 mmHg, Or

• ABIs with results of = 0.7 and = 1.2, Or

• Doppler arterial waveforms, which are triphasic or biphasic at the ankle of the affected foot. For ABPI >1.2 TBI (Toe Brachial Index) > 0.5.

• Patient able to ambulate at home or in the clinic with or without mobility aids

8. The subject is willing to accept treatment with a porcine based product 9. The subject is medically stable, in the opinion of the investigator

Exclusion Criteria:

1. Index Ulcer Assessment:

1. Penetrates down to muscle, tendon, or bone

2. Presence of another diabetic foot ulcer within 2 cm of the index ulcer

3. Index ulcer determined to be due to Active Charcot deformity or previous surgical correction for Charcot deformity.

4. Wounds which occur in relation to major structural abnormalities of the foot, which would include amputations related to osteomyelitis or Charcot deformity

5. Exhibits overt clinical signs and symptoms of infection with cellulitis surrounding the wound margin.

6. Known or suspected local skin malignancy to the index diabetic ulcer

7. Wound duration > one year without intermittent closure

2. Prior therapies - Subjects receiving treatment with any of the following will not be eligible for enrollment:

1. In the last 7 days - Negative pressure wound therapy (wound vac or SNaP®) of the index ulcer

2. In the last 7 days - Hyperbaric oxygen (HBO) therapy

3. In the last 10 days - Chemical debridement, hypochlorous acid or Dakin's solution, medical honey therapy

4. In the last 30 days - Treatment with cytotoxic chemotherapy, application of topical steroids to the ulcer surface, or use of = 14 days of immune-suppressants (including systemic corticosteroids); or, subject is anticipated to require such medications during the course of the study

5. In the last 30 days - study ulcer treatment with any advanced therapy, including, biomedical or topical growth factors, tissue engineered materials (e.g. Apligraf or Dermagraft), sterilized placental allografts (EpiFix, NovaFix, etc.), or other scaffold materials (e.g. OASIS® Wound Matrix, MatriStem Wound Matrix )

6. In the last 30 days - Subject has been on any investigational drug(s) or therapeutic device(s)

7. In the last 8 weeks - Amputation or revascularization (surgical or stenting) to the affected leg

3. Subject criteria that will make subject ineligible for enrollment:

1. Known hypersensitivity to porcine based products

2. Known osteomyelitis or active cellulitis requiring antimicrobial therapy at wound site

3. End stage renal disease requiring dialysis.

4. Immune system disorders including Systemic Lupus Erythematosus (SLE), Acquired Immunodeficiency Syndrome (AIDS) or HIV

5. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator

6. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence)

7. Subjects currently enrolled in this study. Concurrent enrollment in the study is prohibited

8. Subjects currently receiving radiation therapy or chemotherapy

9. Any pathology that would limit the blood supply and compromise healing or non-revascularizable surgical sites

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcer
• Foot Ulcer
• Ulcer

Intervention

Device:
• InnovaMatrix AC porcine placental ECM therapy
All eligible subjects will be treated with a weekly application of sterilized, porcine placental ECM followed by standard of care moist wound therapy and offloading

Locations

Country	Name	City	State
United States	SerenaGroup Austin Research Center	Austin	Texas
United States	Serena Group Buffalo Research Center	Buffalo	New York
United States	SerenaGroup Monroeville	Monroeville	Pennsylvania
United States	Three Rivers Hyperbaric and Wound Center	North Port	Florida
United States	Atrium Medical Center	Stafford	Texas

Sponsors (1)

Lead Sponsor	Collaborator
ConvaTec Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Bacterial burden assessment	Reduction in bacterial burden as assessed by fluorescence imaging using the moleculight imaging device at weeks 4, 8 and 12.	12 weeks
Other	Presence of protease levels	Reduction in host proteases at weeks 4,8, and 12.	12 weeks
Primary	Wound Healing area using digital image	The primary endpoint for the study is assessment of ulcer area at Weeks 6 and 12 using the MolecuLight Imaging Device	12 weeks
Secondary	Wound Closure	Time to complete wound closure as defined by FDA	12 weeks
Secondary	Percentage area reduction	• Rate of wound closure as assessed by wound area measurements determined by weekly percent area reduction	12 weeks
Secondary	Adverse events	Adverse events as reported at weekly treatment visits	12 weeks